Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Zandberg

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
Journal for Immunotherapy of Cancer|April 13, 2022
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trialCharu Aggarwal, Amy Prawira, Scott Antonia, et al.
Oral Oncology|November 10, 2025
Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancerRose Doerfler, Jie Chen, Carl Kim, et al.
The Oncologist|October 25, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutationsMatthew K Nguyen, Mark Jelinek, Arjun Singh, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Integrating Artificial Intelligence-Driven Digital Pathology and Genomics to Establish Patient-Derived Organoids as a Novel Alternative Model for Drug Response in Head and Neck CancerRose Doerfler, Jie Chen, Carl Kim, et al.
Research Square|August 30, 2023
Tumor cell p38 inhibition to overcome immunotherapy resistanceJason J Luke, Rebekah E Dadey, Ryan C Augustin, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
Journal for Immunotherapy of Cancer|April 13, 2022
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trialCharu Aggarwal, Amy Prawira, Scott Antonia, et al.
Oral Oncology|November 10, 2025
Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancerRose Doerfler, Jie Chen, Carl Kim, et al.
The Oncologist|October 25, 2025
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutationsMatthew K Nguyen, Mark Jelinek, Arjun Singh, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Integrating Artificial Intelligence-Driven Digital Pathology and Genomics to Establish Patient-Derived Organoids as a Novel Alternative Model for Drug Response in Head and Neck CancerRose Doerfler, Jie Chen, Carl Kim, et al.
Research Square|August 30, 2023
Tumor cell p38 inhibition to overcome immunotherapy resistanceJason J Luke, Rebekah E Dadey, Ryan C Augustin, et al.
Pageof 10